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In patients with hepatocellular carcinoma (HCC) meeting the Milan criteria (MC), the benefit of locoregional therapies 
(LRTs) in the context of liver transplantation (LT) is still debated. Initial biases in the selection between treated and untreated 
patients have yielded conflicting reported results. The study aimed to identify, using a competing risk analysis, risk factors 
for HCC-dependent LT failure, defined as pretransplant tumor-related delisting or posttransplant recurrence. The study was 
registered at www.clini caltr ials.gov (identification number NCT03723304). In order to offset the initial limitations of the 
investigated population, an inverse probability of treatment weighting (IPTW) analysis was used: 1083 MC-in patients (no 
LRT = 182; LRT = 901) were balanced using 8 variables: age, sex, Model for End-Stage Liver Disease (MELD) value, hepa-
titis C virus status, hepatitis B virus status, largest lesion diameter, number of nodules, and alpha-fetoprotein (AFP). All the 
covariates were available at the first referral. After the IPTW, a pseudo-population of 2019 patients listed for LT was analyzed, 
comparing 2 homogeneous groups of untreated (n = 1077) and LRT-treated (n = 942) patients. Tumor progression after LRT 
was the most important independent risk factor for HCC-dependent failure (subhazard ratio [SHR], 5.62; P < 0.001). Other 
independent risk factors were major tumor diameter, AFP, MELD, patient age, male sex, and period of wait-list registration. 
One single LRT was protective compared with no treatment (SHR, 0.51; P < 0.001). The positive effect was still observed 
when 2-3 treatments were performed (SHR, 0.66; P = 0.02), but it was lost in the case of ≥4 LRTs (SHR, 0.80; P = 0.27). In 
conclusion, for MC-in patients, up to 3 LRTs are beneficial for success in intention-to-treat LT patients, with a 49% to 34% 
reduction in failure risk compared with untreated patients. This benefit is lost if more LRTs are required. A poor response to 
LRT is associated with a higher risk for HCC-dependent transplant failure.
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Liver transplantation (LT) is the best curative treatment of 
hepatocellular carcinoma (HCC) for a cirrhotic liver.(1) In 
oncology, LT is considered a successful procedure when a 
longterm posttransplant tumor-free survival is obtained. 
Conversely, failure is equivalent to pretransplant delist-
ing, posttransplant tumor recurrence, or death.
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Because of allograft scarcity, patients with HCC 
awaiting LT are most often treated using neoadjuvant 
locoregional therapies (LRTs) to delay tumor progres-
sion and minimize the risk of wait-list delisting.(2) 
When the tumor burden meets the Milan criteria 
(MC) at the time of the first referral, this approach is 
called “bridging toward LT.” Two recent international 
guidelines have emphasized the importance of the 
bridging strategy, for it has the potential to reduce the 
risk of pretransplant delisting and posttransplant recur-
rence. This is especially valid in cases where a partial/ 
complete tumor response is achieved before LT.
Accordingly, LRTs have become a standard of care 
for treating the listed patients awaiting transplantation. 
However, although bridging therapies are considered a 
routine approach in the clinical practice, the reported 
quality of evidence regarding their use is poor because 
randomized controlled trials (RCTs) have not yet 
been completed.(3,4) In this setting, RCTs are unten-
able due to logistical and, even more, ethical reasons. 
Consequently, the majority of reported studies com-
pare posttransplant outcomes of treated and untreated 
patients, thereby failing to analyze the clinical course 
from an intention-to-treat point of view.(5,6) Moreover, 
even in studies that include the wait-list period, sub-
stantial differences in tumor burden exist between ini-
tially bridged and untreated HCC patients.(7)
To compensate for these drawbacks, we conducted 
a retrospective analysis of a large European population 
of HCC patients meeting the MC at first referral and 
listed for LT. After “balancing” the cohort for possible 
confounders with an inverse probability of treatment 
weighting (IPTW), we investigated the risk factors 
for tumor-specific failure of LT, focusing on the role 
of LRT.
Patients and Methods
A large multicenter database from the European 
Hepatocellular Cancer and Liver Transplantation 
(EurHeCaLT) Study Group was initially considered 
for the present study. Exclusion criteria were as follows:
1. Age <18 years.
2. MC-out status at first referral.
3. Transplantation or delisting before January 1, 2001.
4. LRT other than transarterial chemoembolization 
(TACE), radiofrequency ablation (RFA), or percu-
taneous ethanol injection (PEI), ie, partial hepatec-
tomy, transarterial radioembolization, or external 
radiotherapy.
5. Incidental HCC.
6. Misdiagnosed mixed hepatocellular-cholangiocellular 
carcinoma or cholangiocellular carcinoma.
A total of 1083 HCC patients meeting MC at first re-
ferral and enlisted for transplant during the period from 
January 1, 2001, to December 31, 2015, were consid-
ered for the IPTW correction. Following the correction 
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for several possible confounders, a pseudo-population 
of 2019 patients was obtained. The study protocol 
received a priori approval by the Institutional Review 
Commitee of the Université  Catholique de Louvain. 
The study was registered at www.clini caltr ials.gov 
(identification number NCT03723304).
statistical analYsis
Continuous variables were reported as medians and 
interquartile ranges (IQRs). Categorical variables were 
described as numbers and percentages. Comparisons 
between groups were made using Fisher’s exact test or 
chi-square test for categorical variables, as appropri-
ate. Student t test was used for continuous variables. 
Missing data relative to study covariates always in-
volved <10% of patients. Missing data were handled 
using the maximum likelihood estimation method.(8)
To compensate for the nonrandomized design of 
this retrospective study, an IPTW was computed.(9) 
The primary goal of IPTW was to achieve causal infer-
ence of an intervention (in this case, treating a patient 
with a LRT or not). In other terms, the IPTW analysis 
created a weighted sample, in which the distribution 
of confounding variables or prognostically important 
covariates was similar between treated and untreated 
subjects. We decided to adopt the IPTW instead of 
a propensity score match with the intent to avoid a 
reduction in the general number of the investigated 
population. A detailed description of the statistical 
strategies implemented for the IPTW construction is 
reported in the Supporting Materials.
Briefly, we generated a propensity score for each 
patient on the original population of 1083 patients. 
The score was created using a multivariate logistic 
regression model considering LRT (no versus yes) as 
the dependent variable. After testing several variables, 
we selected 8 possible clinical relevant confounders as 
covariates: age, sex, Model for End-Stage Liver Disease 
(MELD), hepatitis C virus (HCV)– and hepatitis 
B virus (HBV)–positive status, diameter of the larg-
est lesion, number of nodules, and alpha-fetoprotein 
(AFP) level. All covariates were available at the first 
referral to avoid the risk of a possible immortal time 
bias in covariate selection. Calculating the inverse of 
the obtained propensity score, we “weighted” each 
patient and generated a pseudo-population of 2019 
patients balanced for different confounders available 
at first referral. For example, if a patient presented an 
inverse propensity score number of 5, it was artificially 
“duplicated” for 5 times. Several tests were used to 
confirm the effect of balancing. For continuous vari-
ables, we used the analysis of variance (ANOVA) F test 
and Student t test; for dichotomous variables, we used 
Fisher’s exact test.
A multivariate competing risk analysis was run in 
the IPTW-derived population. Three different com-
peting classes were defined:
1. Curative treatment, consisting of patients who 
survived after LT without recurrence.
2. HCC-dependent failure, defined as patients who 
exhibited tumor-related delisting or posttransplant 
recurrence.
3. HCC-unrelated failure, defined as the sum of pa-
tients who dropped out before LT or died after LT 
for causes other than HCC.
The competing risk model of HCC-dependent 
failure was assessed. HCC-dependent delisting was 
defined as any event of delisting or death on the wait-
ing list (WL) caused by tumor progression. Immediate 
liver decompensation after any HCC treatment, caus-
ing death on the WL, was also considered as an HCC-
dependent cause. Subhazard ratios (SHRs) and 95% 
CIs were reported for significant variables.(10)
Survival analyses were performed using the Kaplan-
Meier method, and the log-rank test was adopted to com-
pare the survival distributions of the examined groups.
Variables with a P  <  0.05 were considered statis-
tically significant. Statistical analyses were run using 
the SPSS, version 24.0 (SPSS Inc., Chicago, IL) 
and STATA, version 14.0 (StataCorp LLC, College 
Station, TX).
Results
cOMparisOn OF treateD 
versUs UntreateD patients 
BeFOre anD aFter iptW
Before the IPTW, the no-LRT and LRT groups con-
tained 182 and 901 patients (n = 1083). After mathe-
matical balancing, a pseudo-population of 2019 patients 
was created (no LRT, n = 1077; LRT, n = 942).
Before the IPTW, several differences between the 
2 groups were observed, such as higher MELD scores 
(P < 0.001) in directly transplanted patients, maximum 
diameter of target lesion (P < 0.001), and number of 
nodules (P = 0.048) in LRT patients (Table 1). A more 
detailed report of the differences between the 2 groups 
before the IPTW is shown in Supporting Table 1.
lai et al. liver transplantatiOn,  July 2019
1026 | Original article
After the weighting, all these variables were bal-
anced, and several statistical tests, such as standardized 
differences, ANOVA F test, Fisher’s exact test, and 
Student t test, confirmed the results (Tables 2 and 3). 
Patient-, tumor- and transplant-related characteristics 
of the post-IPTW pseudo-population are shown in 
Table 4. The only difference between the 2 post-IPTW 
groups was a greater median radiological dimension 
of the target lesion at the time of delisting/LT in the 
no-LRT group (2.0 versus 1.7 cm; P < 0.001).
The median follow-up of the investigated popula-
tion from the time of first referral was 3.4 years (IQR, 
1.3-7.1 years). There were 736 of 942 (78.1%) LRT 
patients who received TACE; 406 (43.1%) received 
RFA or PEI; and 200 (21.2%) patients received multi-
ple types of treatment. For the number of treatments, 
387 of 942 (41.1%) patients had 1 LRT; 346 (36.7%) 
had 2 or 3; and 209 (22.2%) had ≥4 treatments.
FailUre rates in tHe pre- anD 
pOst-iptW pOpUlatiOns
In the original population of 1083 patients, 455 (42.0%) 
patients presented a failure event from the first referral 
taBle 1. patient-, tumor- and transplant-related characteristics of the pre-iptW population
Variables No-LRT Group (n = 182) LRT Group (n = 901) P Value
Age at HCC diagnosis, years* 58 (51-62) 58 (52-63) 0.70
Sex, male* 153 (84.1) 741 (82.2) 0.59
On waiting list during first era (2001-2009) 87 (47.8) 318 (35.3) 0.002
Cause of cirrhosis†
HCV* 79 (43.4) 415 (46.1) 0.57
HBV* 40 (22.0) 155 (17.2) 0.14
Alcohol 60 (33.0) 306 (34.0) 0.86
NASH 8 (4.4) 62 (6.9) 0.25
Laboratory MELD at HCC diagnosis* 12 (11-17) 12 (9-15) <0.001
Radiological tumor features at diagnosis
Maximum diameter of target lesion, cm* 2.0 (1.4-2.5) 2.4 (1.8-3.0) <0.001
Number of lesions* 1 (1-2) 1 (1-2) 0.048
Radiological tumor features at LT or delisting
Maximum diameter of target lesion, cm 2.0 (1.4-2.8) 1.7 (0.0-2.5) <0.001
Number of lesions 1 (1-2) 1 (0-2) 0.27
AFP, ng/mL
At tumor diagnosis* 8.3 (4.0-24.3) 9.4 (4.3-32.6) 0.32
At LT or delisting 8.7 (4.1-33.6) 8.7 (4.0-29.0) 0.48
WT duration, months 3.3 (1.1-9.1) 5.3 (2.3-10.6) 0.57
Post-LRT radiological response at LT or delisting
CR 0 237 (26.3) —
PR 0 258 (28.6) —
SD 0 147 (16.3) —
PD 0 259 (28.7) —
Pathological tumor features‡
Maximum diameter of target lesion, cm 2.0 (1.2-3.0) 2.0 (1.3-3.0) 0.40
Number of lesions 1 (1-2) 1 (1-3) 0.72
MC-out status 30 (17.8) 180 (23.7) 0.10
Multifocality 64 (37.9) 344 (45.4) 0.09
Poor tumor grading 21 (12.4) 105 (13.9) 0.71
Microvascular invasion 31 (18.3) 127 (16.8) 0.65
Post-LRT pathological CR 0 79 (10.4) —
NOTE: Data are given as median (IQR) or n (%).
*Variables used for performing IPTW.
†Multiple pathologies in different patients.
‡Calculated for 927 transplanted patients in the No-LRT (n = 169) and the LRT (n = 758) groups.
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period to the last follow-up; the failure was HCC-
related in 188 (17.4%) and unrelated to HCC in 267 
(24.7%) patients. The failure caused by a delisting event 
was observed in 156 (14.4%) patients. HCC-dependent 
delisting was observed in 97 (9.0%) patients. There 
were 38 (3.5%) patients who died during the waiting 
time (WT) due to non HCC-dependent causes; the 
remaining 21 patients were delisted due to worsened 
liver function unrelated to the LRT. The failure caused 
by post-LT recurrence or death was reported in 299 
(27.6%) patients. A total of 91 (8.4%) recurrences were 
reported after a median time from LT to recurrence 
of 22 months (IQR, 11-47 months), and 32 relapsed 
patients were still alive at the last follow-up. In addi-
tion, 208 (19.2%) patients died after LT due to HCC-
unrelated causes (Supporting Table 2).
In the pseudo-population of 2019 post-IPTW 
patients, 813 (40.3%) patients presented a failure 
event from the first referral period to the last fol-
low-up; the failure was HCC-related in 350 (17.3%) 
and unrelated to HCC in 463 (22.9%) patients. The 
failure caused by a delisting event was observed in 
228 (11.3%) patients. HCC-dependent delisting 
was observed in 146 (7.2%) patients, and 45 (2.2%) 
patients died during the WT due to non HCC-
dependent causes. The remaining 37 patients were 
delisted due to worsened liver function unrelated to 
the LRT. The failure caused by post-LT recurrence 
or death was reported in 585 (29.0%) patients, and 
204 (10.1%) recurrences were reported after a median 
time from LT to recurrence of 22 months (IQR, 
12-47 months). At the last follow-up, 74 relapsed 
patients were still alive; 381 (18.9%) patients died 
after LT due to HCC-unrelated causes (Supporting 
Table 2).
When the number of LRTs was investigated in 
terms of HCC-related failure rates, we performed 2 
separate analyses on the pre- and post-IPTW popu-
lations. In the pre-IPTW population, patients receiv-
ing no LRT presented similar results compared with 
patients treated with 1 LRT (log-rank P = 0.48) or 2-3 
treatments (P = 0.16). However, when the number of 
treatments was ≥4, the failure rates grew accordingly 
(5-year failure rate: 30.8% versus 12.9%; P  =  0.001; 
Fig. 1A).
When the post-IPTW population was investigated, 
we observed similar results. Patients receiving no LRT 
taBle 2. Baseline characteristics for continuous variables of lrt and no-lrt patients in the post-iptW population
Variable by Group Mean SD SE Variance SMD ANOVA F Test Student t Test
Age at listing –3.7 0.73 0.73
No LRT 56.8 8.0 0.2 64.7
LRT 56.5 8.1 0.2 66.1
Laboratory MELD score –5.6 0.12 0.12
No LRT 13.5 5.0 0.2 25.4
LRT 13.2 5.7 0.2 32.9
Major tumor diameter 0 0.76 0.76
No LRT 2.4 1.0 0.03 1.0
LRT 2.4 0.9 0.03 0.9
Number of nodules 0 0.25 0.25
No LRT 1.5 0.8 0.02 0.6
LRT 1.5 0.7 0.02 0.5
Log10 AFP, ng/mL 0.6 0.19 0.19
No LRT 1.9 2.7 1.2 5.4
LRT 1.9 2.6 1.1 5.2
taBle 3. Baseline characteristics for Dichotomous 
variables of lrt and no-lrt patients in the  
post-iptW population
Variable by Group Prevalence SPD Fisher’s Exact Test
Sex, male –4.7 0.19
No LRT 84.6
LRT 82.4
HCV-positive status –2.6 0.47
No LRT 46.6
LRT 45.0
HBV-positive status 1.3 0.73
No LRT 17.4
LRT 18.0
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presented similar results compared with patients treated 
with 1 LRT (log-rank P  =  0.77) or 2-3 treatments 
(P = 0.10). However, when the number of treatments 
was ≥4, the failure rates grew accordingly (5-year fail-
ure rate: 31.6% versus 15.9%; P < 0.001; Fig. 1B).
risK FactOrs OF Hcc-
DepenDent FailUre
The risk factors for the competing event of HCC-
dependent failure in the pre- and post-IPTW 
populations are shown in Table 5. In the pre-IPTW 
population, progressive tumor disease at last radio-
logical assessment was the most important indepen-
dent risk factor for HCC-dependent failure (SHR, 
5.70; P < 0.001), followed by the AFP level (SHR, 
1.53; P <  0.001) at first referral. Other significant 
independent tumor-related risk factors were the di-
ameter of the major lesion, MELD, patient age, and 
period of WL registration. Interestingly, no statisti-
cally significant effect was reported concerning the 
number of LRTs performed. Only receiving 1 LRT 
taBle 4. patient-, tumor- and transplant-related characteristics of the post-iptW population
Variables No-LRT Group (n = 1077) LRT Group (n = 942) P Value
Age at HCC diagnosis, years* 58 (52-63) 58 (52-63) 0.73
Sex, male* 911 (84.6) 776 (82.4) 0.19
On waiting list during first era (2001-2009) 423 (39.3) 349 (37.0) 0.31
Cause of cirrhosis†
HCV* 502 (46.6) 424 (45.0) 0.47
HBV* 187 (17.4) 170 (18.0) 0.73
Alcohol 387 (35.9) 321 (34.1) 0.40
NASH 60 (5.6) 62 (6.6) 0.35
Laboratory MELD at HCC diagnosis* 12 (11-16) 12 (9-15) 0.12
Radiological tumor features at diagnosis
Maximum diameter of target lesion, cm* 2.2 (1.8-3.0) 2.3 (1.7-3.0) 0.75
Number of lesions* 1 (1-2) 1 (1-2) 0.25
Radiological tumor features at LT or delisting
Maximum diameter of target lesion, cm 2.0 (1.6-3.0) 1.7 (0.0-2.4) <0.001
Number of lesions 1 (1-2) 1 (0-2) 0.80
AFP, ng/mL
At tumor diagnosis* 9.2 (4.0-26.8) 9.2 (4.2-32.7) 0.81
At LT or delisting 10.0 (4.0-39.0) 8.7 (4.0-29.2) 0.33
WT duration, months 2.9 (1.0-8.7) 5.2 (2.2-10.6) 0.57
Post-LRT radiological response at LT or delisting
CR 0 253 (26.9) —
PR 0 263 (27.9) —
SD 0 147 (15.6) —
PD 0 275 (29.2) —
Pathological tumor features‡
Maximum diameter of target lesion, cm 2.3 (1.4-3.0) 2.0 (1.3-3.0) 0.11
Number of lesions 1 (1-2) 1 (1-3) 0.48
MC-out status 213 (21.2) 185 (23.6) 0.23
Multifocality 435 (43.2) 357 (45.5) 0.36
Poor tumor grading 141 (14.0) 107 (13.6) 0.84
Microvascular invasion 197 (19.6) 134 (17.1) 0.18
Post-LRT pathological CR 0 81 (10.3) —
NOTE: Data are given as median (IQR) or n (%).
*Variables used for performing IPTW.
†Multiple pathologies in different patients.
‡Calculated for 1791 transplanted patients in the No-LRT (n = 1007) and the LRT (n = 784) groups.
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Fig. 1. (A). HCC-dependent failure rates in the pre-IPTW population stratified by number of LRTs. (B) HCC-dependent failure 
rates in the post-IPTW population stratified by number of LRTs.
taBle 5. competing risk Model for the risk of Hcc-Dependent lt strategy Failure Before and after iptW
Variables β SE SHR 95%CI P Value
Before IPTW
On waiting list during first era (2001-2009) 0.36 0.17 1.43 1.02-1.99 0.04
Sex, male 0.24 0.21 1.26 0.84-1.91 0.26
Age at first referral 0.03 0.01 1.03 1.01-1.05 0.01
MELD at first referral 0.03 0.01 1.03 1.00-1.06 0.02
Diameter of largest tumor at first referral 0.17 0.08 1.19 1.02-1.38 0.03
LRT
No LRT Reference — 1.00 — —
1 LRT –0.54 0.28 0.58 0.34-1.00 0.05
2-3 LRTs –0.32 0.27 0.73 0.43-1.23 0.24
≥4 LRTs –0.09 0.28 0.92 0.53-1.60 0.76
log10 AFP at first referral 0.42 0.10 1.53 1.26-1.86 <0.001
mRECIST PD 1.74 0.17 5.70 4.11-7.90 <0.001
After IPTW
On waiting list during first era (2001-2009) 0.42 0.12 1.52 1.20-1.91 <0.001
Sex, male 0.55 0.18 1.73 1.23-2.44 0.002
Age at first referral 0.42 0.07 1.53 1.34-1.74 <0.001
MELD at first referral 0.03 0.01 1.03 1.01-1.06 0.002
Diameter of largest tumor at first referral 0.27 0.05 1.31 1.18-1.45 <0.001
LRT
No LRT Reference — 1.00 — —
1 LRT –0.67 0.18 0.51 0.36-0.74 <0.001
2-3 LRTs –0.42 0.18 0.66 0.47-0.93 0.02
≥4 LRTs –0.22 0.20 0.80 0.55-1.17 0.27
log10 AFP at first referral 0.48 0.07 1.62 1.41-1.87 <0.001
mRECIST PD 1.73 0.16 5.62 4.10-7.69 <0.001
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merged statistical significance, presenting a trend 
for protection with respect to direct LT (SHR, 0.58; 
P = 0.05).
In the post-IPTW population, progressive tumor 
disease at last radiological assessment was the 
most important independent risk factor for HCC-
dependent failure (SHR, 5.62; P  <  0.001). The 
diameter of the major lesion (SHR, 1.31; P < 0.001) 
and AFP level (SHR, 1.62; P < 0.001) at first refer-
ral were tumor-related risk factors. MELD, patient 
age, male sex, and period of WL registration also 
directly influenced the risk of HCC-dependent 
failure. Patients who received only 1 LRT had the 
best protective effect against failure compared with 
untreated patients (SHR, 0.51; P < 0.001). This ben-
eficial effect was apparent as long as 2-3 treatments 
were done (SHR, 0.66; P  =  0.02), but it was lost 
in case of further treatments (SHR, 0.80; P = 0.27). 
Supporting Table 4 shows the different effects of the 
investigated risk factors in the 2 separate compo-
nents of HCC-related failure, namely, delisting and 
recurrence.
Discussion
In oncology, establishing the superiority of one thera-
peutic strategy over another one requires RCTs, which 
aim to identify proportions of therapeutic failure (ie, 
progressive disease [PD], recurrence, or death) be-
tween the 2 approaches.(11) However, as is usually the 
case, basic oncological principles are overlooked in the 
field of transplant oncology. Given the shortcomings 
of statistical methodology, 3 different reasons might 
explain the lack of clarity about the LRT effect as a 
neoadjuvant treatment in LT.
First, an RCT that compares patients receiving 
upfront transplants with patients receiving LRT first 
as a bridge to LT is difficult to support from an ethi-
cal point of view. Thus, we developed a sophisticated 
statistical approach with the intent to balance a his-
torical population of no-LRT and LRT patients on 
the basis of information available at the first referral 
for LT. The IPTW strongly affected sample size, by 
“artificially” increasing the number of no-LRT patients. 
Nevertheless, such methodology was the only key to 
offset the important, otherwise unresolvable, initial 
selection bias. The balancing effect should be noted 
observing how the results of the competing risk analyses 
changed in the pre- and post-IPTW population: This 
phenomenon was the consequence of the limitation 
of the initial biases presented in the original popula-
tion. The IPTW is prone to conceptual drawbacks, but 
this methodology represents the most rigorous way to 
re-equilibrate the sample to test.(12) Consistently, all 
the tests used to check the successful balancing of the 
2 study groups confirmed the validity of our method.
Second, studies comparing no-LRT and LRT 
patients focus only on posttransplant data, thereby 
failing to obtain intention-to-treat results. It is only 
recently that the importance of intention-to-treat 
analyses in the setting of LT has been recognized.(13-16) 
For the first time, the present study has investigated 
the intention-to-treat effect of LRT against upfront 
LT in MC-in HCC patients.
Third, the overlapping effects of several risk factors 
might lead to inaccurate results because of the absence 
of a competing risk analysis. A competing risk is an 
event that either hides the observation of the event 
in the study (ie, HCC-related outcomes) or alters the 
chance that this event occurs. Recently, the statistical 
analysis of competing risks has also been introduced in 
the setting of HCC and LT.(17) Indeed, the competing 
risk analysis brings about the definition of real-world 
probabilities of a specific event by breaking down spe-
cific causes.
In our study, 2 risks that compete with curative treat-
ment were considered: failure caused by tumor-related 
reasons (ie, pretransplant delisting caused by disease 
progression and posttransplant recurrence) and failure 
caused by nontumor-related events. The conceptual 
evaluation of pretransplant and posttransplant adverse 
events through the same “failure approach” represents a 
novelty in the LT set. In this analysis, disease progres-
sion represented the worst independent risk factor with 
a 5.62-fold increased risk for HCC-dependent failure. 
This observation is in line with many studies showing 
the detrimental role of poor radiological response on 
delisting, intention-to-treat death, transplant benefit, 
posttransplant tumor recurrence, and posttransplant 
death.(5,7,13,14,18,19) The diameter of the largest lesion, 
AFP levels at first referral, and MELD scores were also 
risk factors for HCC-dependent failure by previous 
reports (2,7,13-23)
This study revealed that up to 3 pretransplant LRTs 
were protective compared with no LRT. One LRT 
reduced the risk of intention-to-treat failure by 49%, 
and 2 to 3 treatments decreased this risk by 34%. These 
findings are in line with the recent international guide-
lines, which suggest that bridging LRTs are appropri-
ate in a LT project, despite the heterogeneity of the 
reported data.(3,4)
liver transplantatiOn, vol. 25, no. 7, 2019 lai et al.
Original article | 1031
Interestingly, when we investigated the risk factors 
for HCC-related failure in the pre-IPTW population, 
LRT number failed to be statistically significant. This 
result suggests that the investigation of the LRT effect 
on delisting and posttransplant recurrence should be 
markedly influenced by the initial heterogeneity of 
the investigated population. A recent meta-analysis, 
focusing on LRT and LT, specifically pointed out the 
heterogeneity biases among different studies, which 
are caused by variable demographics (ie, the great 
variability of WT), types of LRT, HCC stages (T1 
versus T2), and treatment dynamics (frequency and 
interval between treatments).(24) Despite these lim-
itations, that meta-analysis partially hinted at our 
results: LRT proved beneficial in terms of global delis-
ting rates (relative risk, 0.19; 95% CI, 0.15-0.24) and 
HCC-dependent delisting (relative risk, 0.11; 95% CI, 
0.07-0.17).(24) When studies comparing treated and 
untreated patients were tested, the relative risk seemed 
protective (0.32; 95% CI, 0.06-1.85). Nonetheless, 
the effect was not statistically significant, probably 
because of biases, imprecision, and inconsistency in 
the included studies.(24) The beneficial effect of LRT 
on the risk of delisting has also been reported in the 
Western and Eastern literature.(7,14,22,23)
The positive effect of upfront LRT was described in 
the recent multicenter US experience comprising 3601 
patients reported by Agopian et al.(5) One LRT was 
protective for the risk of recurrence compared with a 
direct transplant (HR, 0.86); conversely, an increased 
number of treatments raised the risk (≥4 LRT: HR, 
2.5; P < 0.001).
Our results concerning LRT in MC-in HCC 
patients might explain the discrepancy within previ-
ous reports. The different number of bridge treatments 
determines different pretransplant and posttransplant 
outcomes. The decision to perform a direct transplant 
shifts the risk of pretransplant delisting into the risk 
of posttransplant recurrence by eliminating LRT as a 
selection criterion. This phenomenon is also shown in 
Supporting Table 4, in which a higher percentage of 
no-LRT patients experienced recurrence with respect 
to treated patients, whereas LRT patients presented 
more cases of PD and longer WTs (namely, selection 
by time and LRT). This argument has also been clearly 
shown in “fast-track” living donor LT and in studies 
about WT as a possible selector for the risk of post-
transplant recurrence.(25-27) In all of these studies, the 
patients presenting shorter WTs also received a lower 
number of LRTs.
Our study shows that performing a pretransplant 
LRT strategy gives a beneficial effect on post-LT 
results as long as it does not exceed 3 treatments. In 
other terms, when the number of required LRTs for 
stabilizing the tumor is ≤3, the positive effect (namely, 
reducing the posttransplant recurrence) is statistically 
and significantly superior with respect to the negative 
one (namely, increasing the delisting rates). When ≥4 
bridging treatments are necessary with the intent to 
stabilize the tumor before LT, this positive phenome-
non disappears. This negative course is a clear demon-
stration of a tumor selection by treatment: the higher 
the number of LRTs required, the higher the aggres-
siveness of the tumor and the worse the overall results.
Very low 5-year HCC-dependent failure rates can 
be achieved in patients who initially received 1 LRT 
and did not exhibit disease progression after the treat-
ment. Similar data were also observed in a large retro-
spective US analysis performed on 2794 LT patients, 
in which a lower posttransplant recurrence rate was 
reported in patients undergoing LRT, whereas AFP 
and tumor burden were independent risk factors for 
recurrence.(28) In light of these results, we can postulate 
that tumor characteristics prevail over the treatment in 
influencing the ultimate therapeutic results. Still, using 
LRT as a selection tool strongly discriminates between 
patients in terms of posttransplant clinical course.
In an era in which great pressure exists on health 
care quality improvement and cost reduction, our study 
suggests the opportunity to frame a shift in standard 
practice toward LRT in MC-in HCC patients. In our 
study, we observed a risk reduction from 34% to 49% in 
patients receiving ≤3 LRTs, possibly resulting in a sub-
stantial, cost-effective benefit. However, large prospec-
tive cost-effective analyses are needed to confirm this 
effect. Response to LRT seems to be a rather rudimen-
tary but valuable predictive tool, being able to unveil 
tumor biology and, as a test of time, to select patients 
for LT. However, the decision to incorporate LRT as 
a standard approach in MC-in patients should also be 
implemented in light of different local philosophies. 
As an example, it could be argued that LRT could be 
offered as a standard approach in patients with a pre-
dicted WT ≥6 months. On the opposite side, studies 
clarifying the benefit of LRT in centers with shorter 
median times or with living donor programs require 
further evaluation.
The specific role of the LRT method used in our 
series has been only marginally explored in the study. 
In Supporting Table 5, we reported the different risks 
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of delisting, recurrence, and overall HCC-dependent 
failure according to the use of an embolic versus abla-
tive versus combined approach. Preliminary evidence 
exists on the necessity of treating tumors with a com-
binatory approach during the WT, and how it should 
be connected with an increased risk of overall tumor- 
related failure. However, we should consider these 
preliminary results with caution. Further analyses that 
focus on this aspect are required.
Our study has some limitations. The retrospective 
nature of the study impaired our possibility to specify 
in detail the reasons justifying a repetitive treatment 
approach (ie, LRT refractoriness of the target lesion 
versus initial multimodal approach versus treatment of 
new tumors).
Moreover, the study, which covers a long period, 
implies an evolution in the technical aspects of LRT. 
Hence, the study period was limited to the last 2 
decades, and the period was introduced as a variable in 
the multivariate model to correct the results also for this 
possible confounder. The analysis showed that patients 
listed during the first era (2001-2009) fared worse, pos-
sibly because therapeutic approaches improved during 
the second era. One can postulate that excluding the 
cases of hepatic resection, transarterial radioemboliza-
tion, or external radiotherapy should reduce the impact 
of our intention-to-treat analysis. On the other hand, 
we think that considering salvage LT after resection or 
very uncommon strategies, such as radioembolization 
or radiotherapy, should represent a bias, mainly due to 
their neglectable number in the present study.
Another possible limitation concerns intercenter 
differences in the length of WT and dynamics of LRT. 
Although these discrepancies are difficult to resolve, 
the centers belonging to the EurHeCaLT Study Group 
adopt similar approaches and policies in the HCC 
management before LT. Moreover, the difference 
across centers can be statistically beneficial because 
it enriches the variability within patient cohorts and 
brings about more solid statistical results.
Lastly, the use of the IPTW can be criticized for 
the artificial increase in the sample size. However, 
this sophisticated statistical approach is the only way 
forward in removing the initial selection bias. We are 
unable to assert that any residual confounding may 
occur in the study because of an imperfect measure of 
some confounder initially used for the construction of 
the IPTW model. Unfortunately, when this phenome-
non is observed, an adjustment done using this imper-
fect measure does not completely remove the effect of 
the confounding variable. We should honestly under-
line that this latter limit, which derives from the great 
initial difference among LRT and no-LRT patients, 
makes it very difficult to construct a balanced model 
and that it is probably impossible to eliminate in this 
specific setting.
In conclusion, LRT for MC-in HCC patients is 
valuable when considering an intention-to-treat LT 
approach. When comparing treated and untreated 
patients, 1 single and 2-3 LRTs confer a 49% and 34% 
reduction, respectively, in the risk of HCC-dependent 
transplant failure. This beneficial effect disappears 
with ≥4 LRTs because of more aggressive tumor biol-
ogy. Patients who show a poor response to LRT have a 
predictably greater risk for pretransplant tumor-related 
delisting or posttransplant recurrence.
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